MX2021015694A - Composición y métodos para estabilizar formulaciones líquidas de proteínas. - Google Patents

Composición y métodos para estabilizar formulaciones líquidas de proteínas.

Info

Publication number
MX2021015694A
MX2021015694A MX2021015694A MX2021015694A MX2021015694A MX 2021015694 A MX2021015694 A MX 2021015694A MX 2021015694 A MX2021015694 A MX 2021015694A MX 2021015694 A MX2021015694 A MX 2021015694A MX 2021015694 A MX2021015694 A MX 2021015694A
Authority
MX
Mexico
Prior art keywords
methods
composition
liquid formulations
protein formulations
stabilizing liquid
Prior art date
Application number
MX2021015694A
Other languages
English (en)
Inventor
Isidro Angelo Eleazar Zarraga
Anthony Tomlinson
Barthelemy Luc Demeule
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2021015694A publication Critical patent/MX2021015694A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

La presente descripción proporciona formulaciones líquidas que comprenden polipéptidos y tensioactivos. En particular, describe una formulación líquida que comprende un polipéptido y un tensioactivo, en donde al menos aproximadamente 70% (% en peso) del tensioactivo son ésteres de ácidos grasos de polioxietileno (POE) de isosorbida. La invención también proporciona métodos para preparar tales formulaciones líquidas, artículos de fabricación que comprenden tales formulaciones líquidas y métodos para tratar a un paciente con tales formulaciones líquidas.
MX2021015694A 2019-06-28 2020-06-26 Composición y métodos para estabilizar formulaciones líquidas de proteínas. MX2021015694A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962868615P 2019-06-28 2019-06-28
PCT/US2020/039827 WO2020264300A1 (en) 2019-06-28 2020-06-26 Composition and methods for stabilizing liquid protein formulations

Publications (1)

Publication Number Publication Date
MX2021015694A true MX2021015694A (es) 2022-03-11

Family

ID=71728902

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015694A MX2021015694A (es) 2019-06-28 2020-06-26 Composición y métodos para estabilizar formulaciones líquidas de proteínas.

Country Status (13)

Country Link
US (1) US11865177B2 (es)
EP (1) EP3989937A1 (es)
JP (1) JP2022538293A (es)
KR (1) KR20220027940A (es)
CN (1) CN114040754A (es)
AR (1) AR119293A1 (es)
AU (1) AU2020304649A1 (es)
BR (1) BR112021026492A2 (es)
CA (1) CA3141050A1 (es)
IL (1) IL289219A (es)
MX (1) MX2021015694A (es)
TW (1) TW202114641A (es)
WO (1) WO2020264300A1 (es)

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5169770A (en) 1987-12-21 1992-12-08 The University Of Toledo Agrobacterium mediated transformation of germinating plant seeds
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP1997894B1 (en) 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
AU668423B2 (en) 1992-08-17 1996-05-02 Genentech Inc. Bispecific immunoadhesins
EP0794792A1 (en) 1994-12-02 1997-09-17 Chiron Corporation Method of promoting an immune response with a bispecific antibody
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
US20120294866A1 (en) * 2010-01-19 2012-11-22 F. Hoffmann-La Roche Ag Pharmaceutical formulation for proteins
BR112015014853A2 (pt) * 2012-12-21 2017-08-22 Glenmark Pharmaceuticals Sa Formulação farmacêutica, formulação farmacêutica liofilizada, uso de uma formulação farmacêutica e artigo de manufatura
WO2017117311A1 (en) * 2015-12-30 2017-07-06 Genentech, Inc. Formulations with reduced degradation of polysorbate
CN108421046A (zh) * 2018-04-16 2018-08-21 江苏保易制药有限公司 一种新型高纯度药用辅料聚山梨酯及其制备方法

Also Published As

Publication number Publication date
EP3989937A1 (en) 2022-05-04
AU2020304649A1 (en) 2022-01-06
WO2020264300A1 (en) 2020-12-30
AR119293A1 (es) 2021-12-09
IL289219A (en) 2022-02-01
BR112021026492A2 (pt) 2022-02-08
TW202114641A (zh) 2021-04-16
CN114040754A (zh) 2022-02-11
JP2022538293A (ja) 2022-09-01
KR20220027940A (ko) 2022-03-08
CA3141050A1 (en) 2020-12-30
US11865177B2 (en) 2024-01-09
US20210015920A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
PH12020550051A1 (en) Glp-1 compositions and uses thereof
MX2020001403A (es) Nuevos derivados de quinolina.
CY1105167T1 (el) Συνθεσεις πepιεχουσες ενα κοσμετολογικα ενepγο οργανικο οξυ και ενα προϊον οσπριου
IL172835A0 (en) A composition for stabilizing active protein ingredients in pharmaceutical composition containing at least 2 amino acids
PH12020552146A1 (en) Micellar delivery method
MX2017013949A (es) Composiciones mectantes a base de seda y sus metodos.
WO2017053732A3 (en) Composition and method for treating complement-mediated disease
MX2020008125A (es) Composiciones que comprenden berberina.
NZ755442A (en) Topical cyclosporine-containing formulations and uses thereof
WO2020171727A3 (en) Mucoadhesive compositions and uses thereof
MX2019013801A (es) Compuestos de citocina inhibidora de macrofagos-1 (mic-1) y usos de estos.
MX2020010834A (es) Formulacion solida de mezclas insecticidas.
ZA201908610B (en) Il-15 protein complex pharmaceutical composition and uses thereof
MX2021005120A (es) Formulacion aerosolizada.
MX2017008994A (es) Formulacion de peptidos inhibidores mk2.
HK1120794A1 (en) Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them
MX2019004746A (es) Composiciones herbicidas estables.
WO2018189661A3 (en) Methods and compounds for treating diabetes
MX2021015694A (es) Composición y métodos para estabilizar formulaciones líquidas de proteínas.
EP1459758A4 (en) MEANS FOR PROMOTING THE PROLIFERATION AND / OR DIFFERENTIATION OF HEMATOPOETIC STEM CELLS AND / OR HEMATOPOIDIC PRECURSOR CELLS
AU2020378127A8 (en) Compounds as CD73 inhibitors
MX2021015830A (es) Formulaciones penetrantes transdermicas.
MX2019014697A (es) Proteínas del receptor para productos finales de la glicación avanzada (rage) para el tratamiento de fibrosis y enfermedades mediadas por daño al adn.
MX2020010679A (es) Formulacion solida de mezclas insecticidas.
SG10201802129QA (en) A pharmaceutical composition for neuropathic pain